taktic: ipatasertib, endocrine therapy and cdk4/6i for patients with hr /her2- mbc
Published 1 year ago • 117 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
1:12
remaining questions on the use of frontline cdk4/6 inhibitors endocrine therapy
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
5:07
what is the role of cdk4/6 inhibitors in early breast cancer?
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
6:05
cdk4/6 inhibitors & endocrine therapy: selecting a regimen
-
26:08
metastatic hormone positive breast cancer | 2023 ku breast cancer year in review conference
-
4:17
cdk4/6 inhibitors & endocrine therapy in breast cancer
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
5:28
capitello-291: capivasertib fulvestrant for ai-resistant hr /her2- advanced breast cancer
-
1:14
endocrine therapy resistance in er metastatic breast cancer
-
29:09
interactive case: choosing and using cdk4/6 inhibitors in breast cancer - first-line therapy
-
0:50
investigating mechanisms of resistance to cdk4/6 inhibitors
-
17:31
survival analysis of of cdk4/6 inhibitors andendocrine therapy in hr positive,her2 negative day1
-
4:52
cdk4/6 inhibitors in hormone receptor-positive, her2-negative metastatic breast cancer
-
3:38
mbc: cdk4/6 inhibitor patient selection/sequencing